Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Sio Gene Therapies Inc. (AXON) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/14/2023 8-K Quarterly results
Docs: "Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results –Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively"
08/11/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
08/12/2021 8-K Quarterly results
Docs: "Sio Gene Therapies Announces Corporate Updates and Fiscal First Quarter 2021 Financial Results –Completed targeted enrollment of Type II patients in ongoing dose-escalation study of AXO-AAV-GM1 in GM1 gangliosidosis"
06/09/2021 8-K Quarterly results
08/11/2020 8-K Quarterly results
06/10/2020 8-K Quarterly results
Docs: "Axovant Announces Year-End Financial Results and Expected Key Clinical Milestones in Q4 2020"
08/09/2019 8-K Quarterly results
06/11/2019 8-K Quarterly results
Docs: "Axovant Announces Financial Results and Corporate Updates for Fourth Quarter and Fiscal Year Ended March 31, 2019 – Established diversified pipeline of three clinical-stage gene therapy programs for serious neurological disorders including Parkinson’s disease, GM1 gangliosidosis, and Tay-Sachs – SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for Parkinson's disease continues to enroll patients in second dose cohort with data expected in the fourth quarter of 2019 – Reported initial data from Tay-Sachs patient dosed with AXO-AAV-GM2 in March 2019; additional data from patients dosed with AXO-AAV-GM1 and AXO-AAV-GM2 expected in second half of 2019 – Raised $94.5 million in net equity capital from healthcare-dedicated investors in fiscal year ended March 31, 2019 – Net loss for the quarter ended Ma..."
02/07/2019 8-K Quarterly results
08/07/2017 8-K Quarterly results
Docs: "Axovant Announces Fiscal First Quarter Financial Results and Corporate Updates BASEL, Switzerland, Aug. 7, 2017 /"
06/13/2017 8-K Form 8-K - Current report
02/14/2017 8-K Form 8-K - Current report
08/15/2016 8-K Quarterly results
Docs: "Axovant Sciences Announces Expansion of Dementia Pipeline and Reports Financial Results for the First Fiscal Quarter Ended June 30, 2016 - Announces exclusive license agreement with Qaam Pharmaceuticals and announces plan to develop RVT-103, a combination of glycopyrrolate and donepezil, as a potential treatment for patients with dementia, with potential for an eventual triple combination with intepirdine - Announces plan to launch a phase 2 program to study effects of intepirdine on gait and balance in patients with Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease dementia - MINDSET study results and potential NDA filing for intepirdine in mild-to-moderate Alzheimer's disease expected in 2017 - Key clinical data readouts from three programs in Lewy body dementia exp..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy